[1] Shen B, Zhu J, Zhang J, et al. Attenuated mesangial cell proliferation related to store-operated Ca(2+) entry in aged rat: the role of STIM 1 and Orai 1[J]. Age (Dordr), 2013,Epub ahead of print.
[2] Griffin SV, Pichler R, Dittrich M, et al. Cell cycle control in glomerular disease[J]. Springer Semin Immunopathol,2003, 24(4): 441-457.
[3] Su B, Chen X, Zhong C, et al. All-trans retinoic acid inhibits mesangial cell proliferation by up-regulating p21Waf1/Cip1and p27Kip1 and down- regulating Skp2[J]. J Nephrol,2012, 25(6):1031-1040.
[4] Zou L, Wang W, Xu Z, et al. Aldose reductase regulates platelet-derived growth factor-induced proliferation through mediating cell cycle progression in rat mesangial cells[J]. Int J Mol Med,2012, 30(2):409-416.
[5] Xue Y, Tie CR, Li J, et al. Ligustrazine inhibits lipopolysaccharide - induced proliferation by affecting P27, Bcl-2 expression in rat mesangial cells[J]. Eur J Pharmacol,2011, 665(1/2/3):8-12.
[6] 汪霞, 黎七雄. 川芎嗪对脂多糖诱导大鼠肾小球系膜细胞增殖及细胞问粘附因子-1表达的影响[J]. 中国临床药理学与治疗学,2004, 9(4):420-422.
[7] 肖建武, 易著文, 吴小川. 川芎嗪注射液对大鼠肾小球系膜细胞增生的影响[J]. 医药导报, 2004, 23(9):611-613.
[8] Jiang J, Huang X, Wang Y, et al. FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells[J]. Mol Biol Rep, 2012, 39 (8):8243-8250.
[9] Yuan P, Xue H, Zhou L, et al. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide[J]. Nephrol Dial Transplant,2011, 26(7): 2119-2126.
[10]Paccosi S, Musilli C, Mangano G, et al. The monocyte chemotactic protein synthesis inhibitor bindarit prevents mesangial cell proliferation and extracellular matrix remodeling[J]. Pharmacol Res, 2012, 66 (6):526- 535.
[11]Hirasawa Y, Sakai T, Ito M, et al. Advanced-glycation-end- product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta1 receptors and the ERK-MAPK pathway[J]. Eur J Pharmacol,2011, 672 (1/2/ 3):159-168.
[12]Li W, Cui M, Wei Y,et al. Inhibition of the expression of tgf-β1 and ctgf in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist[J]. Cell Physiol Biochem,2012, 30 (3):749-757.
[13]Loeffler I, Hopfer U, Koczan D, et al. Type VIII collagen modulates TGF-β1-induced proliferation of mesangial cells[J]. J Am Soc Nephrol, 2011, 22 (4):649-663.
[14]Davenport AP, Maguire JJ. Pharmacology of renal endothelin receptors[J]. Contrib Nephrol,2011, 172:1-17.
[15]Wang R, Wan Q, Zhang Y, et al. Emodin suppresses interleukin-1β induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK[J]. Life Sciences,2007, 80(26): 2481-2488.
[16]Lu H, Zhou J. HBV X gene transfection upregulates IL-1beta and IL-6 gene expression and induces rat glomerular mesangial cell proliferation[J]. J Huazhong Univ Sci Technolog Med Sci,2008, 28(3):247-250.
[17]Robertson TE, Nikolic-Paterson DJ, Hurst LA, et al. IL-10 induces mesangial cell proliferation via a PDGF-dependent mechanism[J]. Clin Exp Immunol, 2002, 130(2): 241-244.
[18]Kalechman Y, Gafter U, Weinstein T, et al. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3 [J]. J Biol Chem,2004, 279(23):24724-24732.
[19]Wang H, Yin Y, Li W, et al. Over-expression of PDGFR-β promotes PDGF-induced proliferation, migration, and angiogenesis of EPCs through PI3K/Akt signaling pathway [J]. PLoS One,2012, 7(2):e30503.
[20]Woo KT, Lau YK. Proteinuria: clinical signficance and basis for therapy[J]. Singapore Med J,2001, 42(8):385-389.
[21]Singh R, Leehey DJ. Effect of ACE inhibitors on angiotensin II in rat mesangial cells cultured in high glucose[J]. Biochem Biophys Res Commun,2007, 357(4):1040-1045.
[22]Qiu G, Ji Z. AngII-induced glomerular mesangial cell proliferation inhibited by losartan via changes in intracellular calcium ion concentration[J]. Clin Exp Med,2013,Epub ahead of print.
[23]Robles NR. Calcium antagonists and renal failure progression[J]. Ren Fail,2008, 30(3):247-255.
[24]Yasuhisa K. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease[J]. Med Res Rev, 2003, 23(1):15-31.
[25]Mulgrew CJ, Cove-Smith A, McLatchie LM, et al. Inhibition of human mesangial cell proliferation by targeting T-type calcium channels[J]. Nephron Exp Nephrol,2009, 113(2):e77-88.
[26]Bokemeyer D, Panek D, Kitahara M, et al. The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis [J]. Nephrol Dial Transplant, 2007, 22(12):3431-3441.
[27]Wang B, Zhang A, Zheng J, et al. Gong J Bufalin inhibits platelet-derived growth factor-BB-induced mesangial cell proliferation through mediating cell cycle progression[J]. Biol Pharm Bull,2011, 34(7):967-973.
[28]Danilewicz M, Wagrowska-Danilewicz M. Differential glomerular immuno- expression of matrix metalloproteinases MMP-2 and MMP-9 in idiopathic IgA nephropathy and Schoenlein-Henoch nephritis[J]. Folia Histochem Cytobiol,2010, 48(1):63-67.
[29]Daniel C, Duffield J, Brunner T, et al. Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells[J]. J Pharmacol Exp Ther,2001, 297(1):57-68.
[30]Wang W, Chan YH, Lee W, et al. Effect of rapamycin and FK506 on mesangial cell proliferation[J]. Transplant Proc,2001, 33(1/2):1036-1037.
[31]Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy[J]. Proc Natl Acad Sci USA,2002, 99(12):8301-8305.
[32]Zou L, Wang W, Xu Z, et al. Aldose reductase regulates platelet-derived growth factor-induced proliferation through mediating cell cycle progression in rat mesangial cells[J]. Int J Mol Med, 2012, 30(2):409-416.
[33]Su YX, Deng HC, Zhang MX, et al. Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of rapamycin-mediated survival pathway by adenosine 5-monophosphate-activated protein kinase[J]. Horm Metab Res,2012, 44(1):21-27.
[34]Cobanolu B, Toskala E, Ural A, et al. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis[J]. Curr Allergy Asthma Rep,2013, 13(2):203-208.
[35]Park J, Song KH, Ha H. Fractalkine increases mesangial cell proliferation through reactive xxygen species and mitogen-activated protein kinases[J]. Transplant Proc,2012, 44(4):1026-1028.
[36]Dubey RK, Jackson EK. Estrogen induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms[J]. Am J Physiol Renal Physiol,2001, 280 (3):F365-388.
[37]Xiao S, Gillespie DG, Baylis C, et al. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth[J]. Hypertension,2001, 37(2 part 2):645-650.
[38]Dubey RK, Gillespie DG, Keller PJ, et al. Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells[J]. Hypertension,2002, 39(2 part 2):418-424.
[39]Dubey RK, Zacharia LC, Gillespie DG, et al. Catecholamines block the antimitogenic effect of estradiol on human glomerular mesangial cells[J]. Hypertension,2003, 42(3):349-355.
[40]Song L, Xiao W, Templeton DM. Low-concentra-tion heparin suppresses ionomycin-activated CAMK-II/EGF receptor-and ERK-mediated signaling in mesangial cells[J]. J Cell Physiol,2010, 224(2):484-490. |
